NaviFUS Corporation (6872) AI Stock Analysis

NaviFUS Corporation

(TPEx:6872)

Select Model

Rating:42Neutral

Price Target:TWD 16.50▼(-8.33% Downside)

Action:initiatedcoverage

Date:11/10/26

The overall score of 42 is heavily pressured by poor financial performance, which carries the highest weight. Accelerating cash burn and collapsing gross margins are the most significant risks, despite a strong, debt-free balance sheet. Technical trends reinforce the weakness, with the stock in a clear downtrend across all timeframes. The negative P/E ratio and lack of dividend yield further detract from the investment case.

Positive Factors

Low financial leverageVery low leverage reduces solvency pressure and limits interest-related strain while the company works to commercialize its technology. This provides greater financial flexibility than a heavily indebted structure and may help NaviFUS absorb continuing operating losses over the next several quarters.

Negative Factors

Sharp revenue contractionThe 2025 revenue decline indicates a material setback in commercialization momentum after several years of growth. A smaller revenue base makes it harder to absorb fixed research, development, and operating costs, increasing the risk that profitability remains distant.

NaviFUS Corporation (6872) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.29B
Dividend Yield: ―
Average Volume (3M): 179.96K
Price to Earnings (P/E): -8.7
Beta (1Y): 0.33
Revenue Growth: 42.14%
EPS Growth: -19.74%
Country: TW
Employees: 20
Sector: General
Sector Strength: 55
Industry: Medical - Devices

NaviFUS Corporation Business Overview & Revenue Model

Company Description

NaviFUS Corporation operates within the medical device sector, specializing in the development and commercialization of advanced focused ultrasound (FUS) technologies tailored for neurological applications. The company's primary offering is NaviFUS,...

NaviFUS Corporation Financial Statement Overview

Summary

Financial performance is weak, driven by deteriorating income and cash flow trends. The Income Statement (Score 18) shows volatile revenue and collapsing gross margins, while Cash Flow (Score 15) reflects accelerating cash burn. The strong Balance Sheet (Score 72) provides a critical cushion, but operational losses are eroding equity. Overall, the company is financially strained with no clear path to profitability.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Mar 2024	Mar 2023	Dec 2021
Income Statement
Total Revenue	27.25M	10.48M	27.53M	22.48M	19.53M	0
Gross Profit	3.50M	-2.79M	9.68M	11.83M	16.49M	-9.49M
EBITDA	-143.21M	-133.30M	-77.03M	-55.80M	-53.84M	-73.14M
Net Income	-151.30M	-148.46M	-95.13M	-65.73M	-63.59M	-82.80M
Balance Sheet
Total Assets	571.51M	635.99M	546.69M	490.54M	524.07M	589.92M
Cash, Cash Equivalents and Short-Term Investments	375.47M	436.56M	374.85M	373.58M	465.13M	544.62M
Total Debt	16.38M	20.18M	27.53M	32.69M	190.00K	2.46M
Total Liabilities	75.48M	70.61M	54.04M	53.40M	21.19M	25.88M
Stockholders Equity	485.99M	555.64M	481.50M	423.00M	484.95M	546.44M
Cash Flow
Free Cash Flow	-98.62M	-138.85M	-133.87M	-88.14M	-81.58M	-60.76M
Operating Cash Flow	-78.28M	-91.24M	-77.71M	-48.69M	-57.36M	-52.11M
Investing Cash Flow	530.00K	-94.28M	-58.08M	-15.76M	-24.91M	-53.33M
Financing Cash Flow	-7.39M	210.31M	143.02M	-3.59M	-2.27M	294.56M

NaviFUS Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6872 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4161	61Neutral	TWD 1.22B	11.45	―	3.32%	7.54%	35.87%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4109	45Neutral	TWD 1.21B	256.25	―	1.95%	13.00%	902.22%
TW:6872	42Neutral	TWD 1.26B	-8.71	―	―	42.14%	-19.74%

* General Sector Average

Performance Comparison

TW:6872 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6872	NaviFUS Corporation	18.00	-1.90	-9.55%
TW:4109	Jia Jie Biomedical Co., Ltd.	10.20	-5.56	-35.28%
TW:4161	Bioptik Technology, Inc.	20.90	-4.70	-18.36%
TW:6543	Perfect Medical Industry Co., Ltd.	17.00	-10.51	-38.21%
TW:6847	PuriBlood Medical Co.,Ltd.	68.00	-2.29	-3.25%
TW:7814	Horien Biochemical Technology Co., Ltd.	26.60	-12.05	-31.18%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

NaviFUS Corporation AI Stock Analysis